Abstract
The complement system's C3a receptor (C3aR) is a key driver of inflammation, making it a prime therapeutic target. However, the pharmacological nature of the small-molecule modulator JR14a has remained controversial. Here, we present high-resolution cryo-EM structures of C3aR bound to JR14a, alongside functional signaling and chemotaxis assays. Our results definitively characterize JR14a as a potent agonist that occupies a unique minor pocket within the receptor. This structural insight explains JR14a's high selectivity for C3aR over the closely related C5aR1, providing a framework for the development of next-generation anti-inflammatory drugs.
Introduction
The complement system is an essential component of innate immunity, yet its dysregulation is linked to various chronic inflammatory and neurodegenerative conditions. The C3a receptor (C3aR), a G protein-coupled receptor (GPCR), is activated by the peptide C3a to initiate pro-inflammatory signaling. While C3a is the endogenous ligand, its peptidic nature limits its therapeutic utility. Small-molecule modulators like JR14a offer a more stable alternative, but conflicting reports on whether JR14a acts as an agonist or antagonist have hindered drug development.
Functional Characterization: JR14a as a Potent Agonist
To resolve the debate regarding JR14a's activity, researchers conducted a series of functional assays. In cAMP inhibition assays using HEK293 and THP-1 cells, JR14a demonstrated higher potency and efficacy than the natural C3a peptide in activating the $G_i$ signaling pathway. Furthermore, JR14a successfully induced chemotaxis in neutrophils and monocytes, a definitive marker of receptor activation. These findings confirm that JR14a is a full agonist of C3aR.
Structural Architecture and the "Minor Pocket"
Cryo-electron microscopy (cryo-EM) was used to determine the structures of C3aR in complex with JR14a, both with and without the heterotrimeric $G_i$ protein, at resolutions of 2.9 Å and 3.0 Å. The structures reveal that JR14a adopts a distinct "λ" shape within the orthosteric binding site. Unlike the natural C3a peptide, which binds in a hook-like conformation, JR14a extends into a unique "minor pocket" formed by transmembrane helices TM1, TM2, and TM7. The JR14a-bound C3aR is structurally almost identical to the C3a-bound version (RMSD < 0.7 Å), confirming it locks the receptor into a fully active state.
Critical interactions were identified between the arginine methyl ester (Arg-OMe) moiety of JR14a and residues D417, R340, and Y393. Mutagenesis studies confirmed that these contacts are essential for JR14a-mediated signaling; swapping these residues completely abolished the molecule's activity.
Molecular Basis for C3aR Selectivity
A key finding of this study is the structural basis for JR14a's selectivity for C3aR over the C5a receptor (C5aR1). In C5aR1, the corresponding minor pocket is obstructed by bulky residues (F44 and L92). By mutating these residues in C5aR1 to the smaller amino acids found in C3aR (L30 and S78), researchers were able to confer JR14a sensitivity to C5aR1, proving that steric hindrance in the minor pocket is the primary determinant of selectivity.
Conclusion
By resolving the high-resolution structure of the C3aR-JR14a complex, this study settles the long-standing controversy over JR14a's pharmacological profile. The discovery of the unique minor pocket binding mode provides a precise blueprint for designing highly selective C3aR modulators. Future efforts may leverage these insights to develop biased ligands that maximize therapeutic benefits while minimizing adverse effects.
Summary updated